Showing results (41-50 of 123) with videos related to
Sort By:
Pageof 13
The Journal of Experimental Medicine|September 15, 2004
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tractSaurabh Mehandru, Michael A Poles, Klara Tenner-Racz, et al.Journal of Addiction Research & Therapy|March 1, 2016
Behavioural, Mucosal and Systemic Immune Parameters in HIV-infected and Uninfected Injection Drug UsersSaurabh Mehandru, Sherry Deren, Sung-Yeon Kang, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2012
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York CityDelivette Castor, Andrea Low, Teresa Evering, et al.AIDS Patient Care and Stds|August 11, 2016
Challenges in Recruiting People Who Use Drugs for HIV-Related Biomedical Research: Perspectives from the FieldPedro Batista, Sherry Deren, Angela Banfield, et al.Journal of Virology|September 16, 2004
Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infectionMichele Di Mascio, Martin Markowitz, Michael Louie, et al.Proceedings of the National Academy of Sciences of the United States of America|January 19, 2007
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypesLeonia Bozzacco, Christine Trumpfheller, Frederick P Siegal, et al.Journal of Virology|June 20, 2002
Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failureGustavo H Kijak, Viviana Simon, Peter Balfe, et al.The Journal of Infectious Diseases|August 31, 2006
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infectionFrederick M Hecht, Lei Wang, Ann Collier, et al.The Journal of Antimicrobial Chemotherapy|February 11, 2014
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adultsMartin Markowitz, Andrew Zolopa, Kathleen Squires, et al.Journal of Virology|November 27, 2004
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10Saurabh Mehandru, Terri Wrin, Justin Galovich, et al.Pageof 13